0001082554-20-000012.txt : 20200729 0001082554-20-000012.hdr.sgml : 20200729 20200729062626 ACCESSION NUMBER: 0001082554-20-000012 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200729 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200729 DATE AS OF CHANGE: 20200729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNITED THERAPEUTICS Corp CENTRAL INDEX KEY: 0001082554 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521984749 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26301 FILM NUMBER: 201055655 BUSINESS ADDRESS: STREET 1: 1040 SPRING ST CITY: SILVER SPRING STATE: MD ZIP: 20910 BUSINESS PHONE: 3016089292 MAIL ADDRESS: STREET 1: 1040 SPRING ST CITY: SILVER SPRING STATE: MD ZIP: 20910 FORMER COMPANY: FORMER CONFORMED NAME: UNITED THERAPEUTICS CORP DATE OF NAME CHANGE: 19990324 8-K 1 uthrq22020form8-k.htm 8-K Document
false0001082554 0001082554 2020-07-29 2020-07-29


 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 29, 2020
 
United Therapeutics Corporation
(Exact Name of Registrant as Specified in Charter)
Delaware
000-26301
52-1984749
(State or Other
Jurisdiction of
Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification Number)
 
1040 Spring Street
 
Silver Spring,

MD
20910
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant’s telephone number, including area code:
(301) 608-9292
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of exchange on which registered
Common Stock, par value $0.01 per share
UTHR
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 




Item 2.02.  Results of Operations and Financial Condition.
 
On July 29, 2020, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended June 30, 2020.
 
A copy of the press release is attached hereto as Exhibit 99.1.
 
Item 9.01.  Exhibits
 
This information shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
 
(d)  Exhibits
 
Exhibit No.
 
Description of Exhibit
 
 
 

 
104

 
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.







SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
UNITED THERAPEUTICS CORPORATION
 
 
 
 
 
Dated: July 29, 2020
By:
/s/ Paul A. Mahon
 
Name:
Paul A. Mahon
 
Title:
General Counsel






 EX-99.1 2 uthrq22020-ex991.htm EXHIBIT 99.1 Exhibit


Exhibit 99.1
For Immediate Release
Contact: Dewey Steadman
Phone: (202) 919-4097
Email: ir@unither.com

United Therapeutics Corporation Reports
Second Quarter 2020 Financial Results

- Second quarter Orenitram® revenue growth of 40% year-over-year
- INCREASE sNDA submitted to FDA
Silver Spring, Md. and Research Triangle Park, N.C., July 29, 2020: United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2020.
“I am pleased with our performance during the second quarter, and feel that we are well positioned for a return to revenue growth in the near term as our prescriptions and new patient starts have been approaching pre-pandemic levels,” said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. “Orenitram continues to grow following our FREEDOM-EV label update, and we believe the INCREASE study results will lead to significant Tyvaso growth. In addition, our new subcutaneous Remunity Pump and intravenous Implantable System for Remodulin products, while delayed, are nevertheless forthcoming in the near term as manufacturing and regulatory requests get resolved.”
SECOND QUARTER 2020 FINANCIAL RESULTS
Key financial highlights include (dollars in millions, except per share data):
 
Three Months Ended
June 30,
 
Dollar Change
 
Percentage Change
 
2020
 
2019
 
 
 
 
 
 
 
 
 
 
Revenues
$
362.0

 
$
373.6

 
$
(11.6
)
 
(3
)%
Net income
$
107.1

 
$
205.1

 
$
(98.0
)
 
(48
)%
Non-GAAP earnings(1)
$
163.2

 
$
159.7

 
$
3.5

 
2
 %
Net income, per basic share
$
2.43

 
$
4.68

 
$
(2.25
)
 
(48
)%
Net income, per diluted share
$
2.41

 
$
4.66

 
$
(2.25
)
 
(48
)%
Non-GAAP earnings, per diluted share(1)
$
3.68

 
$
3.63

 
$
0.05

 
1
 %
________________________
(1)
See definition of non-GAAP earnings, a non-GAAP financial measure, and a reconciliation of net income to non-GAAP earnings below.

1


Revenues
The table below summarizes the components of total revenues (dollars in millions):
 
Three Months Ended
June 30,
 
Dollar
Change
 
Percentage
Change
 
2020
 
2019
 
 
Net product sales:
 

 
 

 
 
 
 

Remodulin®
$
119.0

 
$
155.8

 
$
(36.8
)
 
(24
)%
Tyvaso®
119.2

 
109.6

 
9.6

 
9
 %
Orenitram®
75.4

 
54.0

 
21.4

 
40
 %
Unituxin®
29.0

 
25.1

 
3.9

 
16
 %
Adcirca®
19.4

 
29.1

 
(9.7
)
 
(33
)%
  Total revenues
$
362.0

 
$
373.6

 
$
(11.6
)
 
(3
)%
The reduction in Remodulin revenue was driven primarily by a reduction in quantities sold in Europe, which we believe resulted from generic competition and the impact of COVID-19, and to a lesser extent, by a reduction in quantities sold in the United States, which we believe resulted from COVID-19 related reductions in new patient prescriptions and new patient starts due to access restrictions at physician offices. The growth in Orenitram revenue resulted primarily from an increase in quantities sold, as the number of patients being treated with Orenitram has grown following the update to Orenitram’s labeling to reflect the FREEDOM-EV clinical trial results. The decrease in Adcirca revenues was driven by continued erosion of market share due to generic competition.
Expenses
Cost of product sales. The table below summarizes cost of product sales by major category (dollars in millions): 
 
Three Months Ended
June 30,
 
Dollar Change
 
Percentage Change
 
2020
 
2019
 
 
Category:
 

 
 

 
 
 
 

Cost of product sales
$
23.9

 
$
28.9

 
$
(5.0
)
 
(17
)%
Share-based compensation expense (benefit)(1)
2.0

 
(2.2
)
 
4.2

 
191
 %
Total cost of product sales
$
25.9

 
$
26.7

 
$
(0.8
)
 
(3
)%
________________________
(1)
Refer to Share-based compensation below.
Research and development expense. The table below summarizes research and development expense by major category (dollars in millions):
 
Three Months Ended
June 30,
 
Dollar Change
 
Percentage Change
 
2020
 
2019
 
 
Category:
 

 
 

 
 
 
 

Research and development projects
$
78.3

 
$
95.8

 
$
(17.5
)
 
(18
)%
Share-based compensation expense (benefit)(1)
11.4

 
(9.9
)
 
21.3

 
215
 %
Total research and development expense
$
89.7

 
$
85.9

 
$
3.8

 
4
 %
________________________
(1)
Refer to Share-based compensation below.

2


Selling, general, and administrative expense. The table below summarizes selling, general, and administrative expense by major category (dollars in millions):
 
Three Months Ended
June 30,
 
Dollar Change
 
Percentage Change
 
2020
 
2019
 
 
Category:
 

 
 

 
 
 
 

General and administrative
$
54.8

 
$
51.0

 
$
3.8

 
7
 %
Sales and marketing
12.7

 
13.7

 
(1.0
)
 
(7
)%
Share-based compensation expense (benefit)(1)
38.4

 
(25.1
)
 
63.5

 
253
 %
Total selling, general, and administrative expense
$
105.9

 
$
39.6

 
$
66.3

 
167
 %
________________________
(1)    Refer to Share-based compensation below.
Share-based compensation. The table below summarizes share-based compensation expense (benefit) by major category (dollars in millions):
 
Three Months Ended
June 30,
 
Dollar Change
 
Percentage Change
 
2020
 
2019
 
 
Category:
 

 
 

 
 
 
 

Stock options
$
9.2

 
$
18.1

 
$
(8.9
)
 
(49
)%
Restricted stock units
5.5

 
3.8

 
1.7

 
45
 %
Share tracking awards plan (STAP)
36.7

 
(59.4
)
 
96.1

 
162
 %
Employee stock purchase plan
0.4

 
0.3

 
0.1

 
33
 %
Total share-based compensation expense (benefit)
$
51.8

 
$
(37.2
)
 
$
89.0

 
239
 %
The increase in share-based compensation expense for the three months ended June 30, 2020, as compared to the same period in 2019, was primarily due to an increase in STAP expense driven by a 28 percent increase in our stock price for the three months ended June 30, 2020, as compared to a 33 percent decrease in our stock price for the same period in 2019.
Other (Expense) Income, Net. The change in other (expense) income, net for the three months ended June 30, 2020, as compared to the same period in 2019, was primarily due to net unrealized and realized gains and losses on equity securities.

3


Non-GAAP Earnings
Non-GAAP earnings is defined as net income, adjusted for: (i) share-based compensation expense (including expenses relating to stock options, restricted stock units, share tracking awards, and our employee stock purchase plan); (ii) net unrealized and realized losses (gains) on equity securities; (iii) impairment charges; (iv) license-related fees; and (v) tax impact on non-GAAP earnings adjustments.
A reconciliation of net income to non-GAAP earnings is presented below (in millions, except per share data):
 
Three Months Ended
June 30,
 
2020
 
2019
Net income, as reported
$
107.1

 
$
205.1

Adjusted for the following items:
 
 
 
Share-based compensation expense (benefit)(1)
51.8

 
(37.2
)
Net unrealized and realized losses (gains) on equity securities(2)
8.9

 
(29.5
)
Impairment charges(3)
—

 
8.8

License-related fees(3)
12.5

 
—

Tax (benefit) expense
(17.1
)
 
12.5

Non-GAAP earnings
$
163.2

 
$
159.7

Non-GAAP earnings per share:
 
 
 
Basic
$
3.70

 
$
3.65

Diluted
$
3.68

 
$
3.63

Weighted average number of common shares outstanding:
 
 
 
  Basic
44.1

 
43.8

  Diluted
44.4

 
44.0

________________________
(1)
Recorded within operating expenses on our consolidated statements of operations.
(2)
Recorded within “other (expense) income, net” on our consolidated statements of operations.
(3)
Recorded within research and development on our consolidated statements of operations.
NEW PRODUCT COMMERCIALIZATION UPDATE
In our near-term time horizon, we plan to launch Tyvaso for a new indication, and to launch three new products for pulmonary arterial hypertension (PAH): the Remunity™ Pump, the Trevyent® system, and the Implantable System for Remodulin.
Tyvaso in pulmonary hypertension due to interstitial lung disease (PH-ILD) — INCREASE. On February 24, 2020, we reported that the INCREASE study of Tyvaso in patients with PH-ILD met its primary endpoint of demonstrating improvement in six-minute walk distance (6MWD). Tyvaso also showed benefits across several key subgroups, including etiology of PH-ILD, disease severity, age, gender, baseline hemodynamics, and dose. Significant improvements were also observed in each of the study’s secondary endpoints, including reduction in the cardiac biomarker NT-proBNP, time to first clinical worsening event, change in peak 6MWD at Week 12, and change in trough 6MWD at week 15. Treatment with Tyvaso of up to 12 breaths per session, four times daily, in the INCREASE study was well tolerated and the safety profile was consistent with previous Tyvaso studies and known prostacyclin-related adverse events.
We presented these and other highlights of the INCREASE data at a recent virtual session of the American Thoracic Society entitled “Inhaled Treprostinil in Interstitial Lung Disease-Associated Pulmonary Hypertension: The INCREASE Study.” We expect to make the full results of the study available through upcoming journal publications. In addition, we recently submitted the INCREASE study results to the U.S. Food and Drug Administration (FDA) in support of an efficacy supplement to the Tyvaso new drug application (sNDA), which we expect to result in revised labeling reflecting the outcome of the INCREASE study.

4


Remunity Pump for Remodulin. We commenced launch activities for the Remunity Pump for Remodulin, including shipping training devices to specialty pharmacies and certain health care practitioners, and entering into agreements with specialty pharmacies to purchase Remunity Pumps and accessories and to pre-fill the Remunity cartridges exclusively with Remodulin. We also confirmed with the relevant Centers for Medicare & Medicaid Services Pricing, Data Analysis, and Coding Contractor that the Remunity Pump will be treated as durable medical equipment under the Medicare Part B Durable Medical Equipment program, and will share the same billing codes and billing guidance as existing subcutaneous pumps currently used with Remodulin. We started working with large PAH medical centers to identify patient candidates for the Remunity Pump, and have been training staff at these centers on how to use the product. However, the timing of our ability to commence commercial sales has been delayed due to pandemic-related issues impacting the ability of our partner, DEKA Research & Development Corp. (DEKA), to secure certain components and raw materials necessary to manufacture a continuous supply of pumps, pump disposables, and pump controllers. We are working closely with DEKA to build safety stock of these components and raw materials to a level that would allow us to withstand a significant supplier disruption without adverse impact to our patient base. We implemented this strategy due to the increasing COVID-19 infection rates observed in the United States during the second quarter of 2020, as many of the Remunity Pump component suppliers are located domestically. We are working to commence commercial sales of the Remunity Pump in the near-term, but we cannot predict the precise timing due to the factors described above, as well as the potential for additional pandemic-related constraints that physicians and patients may experience.
Trevyent. We submitted a 505(b)(1) new drug application (NDA) to the FDA for our Trevyent disposable treprostinil pump system in June 2019. In April 2020, the FDA issued a complete response letter (CRL) related to our NDA indicating that some of the deficiencies previously raised by the FDA had not yet been addressed to its satisfaction. We have one year from the date of the CRL to resubmit our NDA to the FDA, which is expected to trigger a six-month review period by the FDA. We are preparing our NDA resubmission, which we expect to file in 2021.
Implantable System for Remodulin (ISR). Developed in collaboration with Medtronic, Inc. (Medtronic), the premarket approval application (PMA) for the ISR was approved by the FDA in December 2017. However, our ability to launch the product is subject to Medtronic satisfying various conditions to its PMA approval. Medtronic continues to work toward satisfying these conditions, but in December 2019, due to FDA communications, Medtronic informed us that these conditions will not be satisfied in 2020. As such we expect a delay in the ISR launch until 2021.
RESEARCH AND DEVELOPMENT UPDATE
Our clinical studies remain open, and enrollment of new patients has resumed at select study sites for certain studies. Most of our ongoing clinical studies paused enrollment during the first quarter of 2020 due to the pandemic, but patients already enrolled in studies continue to receive the study drug and complete necessary clinical evaluations as appropriate.
The following studies have since re-opened enrollment at select sites:
•
the BREEZE and pivotal pharmacokinetics studies of Treprostinil Technosphere®;
•
the ADVANCE OUTCOMES study of ralinepag;
•
the SAPPHIRE study of Aurora-GT™;
•
our phase I study of Unexisome™ for bronchopulmonary dysplasia; and
•
our phase I study of OreniPro™.
We have also recommenced startup activities for the ADVANCE CAPACITY study of ralinepag. While enrollment of the PERFECT study of Tyvaso in pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) remains paused, we are continuing new clinical site startup activities for this study.
Although we re-opened enrollment of certain studies at a limited number of clinical trial sites, it is difficult to predict when we will be able to reopen enrollment at additional sites for these studies, and whether we will experience further disruptions as the pandemic unfolds. In addition, it is unclear what impact the pandemic may have on the timing of future studies, such as TETON. As such, we expect that completion and data readouts for several of our ongoing and planned studies will be delayed, but we do not currently expect delays of our near-, medium-, and long-term windows for product launch plans. To mitigate potential delays, we are expanding our efforts to enter into contracts with additional clinical study sites and complete other site activation activities for certain studies where practicable so that we may rapidly resume enrollment of our clinical studies at the appropriate time.

5


Treprostinil Technosphere dry powder inhaler — BREEZE. The BREEZE study (NCT03950739) seeks to evaluate 45 patients on a stable dose of Tyvaso after switching to our new dry powder inhaler (DPI) form of treprostinil, which we licensed from MannKind. The primary endpoint of the study is the number of subjects with treatment-emergent adverse events after three weeks of treatment with the DPI. In March 2020, we commenced a second clinical study in healthy volunteers to compare the pharmacokinetics of Treprostinil Technosphere to Tyvaso. We expect results of these two studies, combined with long-term stability studies of the DPI product, will form the basis of a 505(b)(1) NDA to the FDA.
Unituxin in relapsed/refractory neuroblastoma — ANBL1221. We are pursuing an indication expansion for Unituxin for the treatment of pediatric patients with relapsed or refractory neuroblastoma based on the results of the Children’s Oncology Group’s ANBL1221 study (NCT01767194). We met with the FDA in April of this year to discuss the content needed to support a supplemental biologics license application (BLA). We are working with Children’s Oncology Group to secure additional information ahead of a potential supplemental BLA.
Tyvaso in PH-COPD — PERFECT. The PERFECT study (NCT03496623) seeks to evaluate Tyvaso in patients with PH-COPD. In a 30-week crossover study, 136 subjects will be randomized between inhaled treprostinil and placebo for a 26-week treatment period. The primary endpoint of the study is the change in 6MWD from baseline to week 12 on active treatment compared to placebo. A contingent design for the study allows for the evaluation of 314 patients in two parallel groups.
Tyvaso in patients with chronic fibrosing interstitial lung disease (CFILD) — TETON. We are commencing a new phase III registration study called TETON, which is a randomized, double-blind, placebo-controlled, 24-week, phase III study of Tyvaso in subjects with CFILD (which includes patients with idiopathic interstitial pneumonias, chronic hypersensitivity pneumonitis, and environmental/occupational lung disease). Subjects will be randomized in a 1:1 ratio to receive inhaled treprostinil or placebo. The primary endpoint of this study is planned to be the change from baseline to week 24 in absolute forced vital capacity (FVC). This study was prompted by data from the INCREASE study, which demonstrated improvements in parameters of lung function in pulmonary hypertension patients with fibrotic lung disease (FVC and reduced exacerbations of underlying lung disease).
Ralinepag phase III development program — ADVANCE CAPACITY and ADVANCE OUTCOMES. We have two ongoing phase III clinical studies to support the potential registration of oral ralinepag for PAH.
•
ADVANCE CAPACITY. The phase III ADVANCE CAPACITY study (NCT04084678) seeks to evaluate 193 subjects with PAH, randomized between oral ralinepag and placebo at a 2:1 ratio, along with PAH background therapy, for 28 weeks. The primary endpoint of the study is the change from baseline to week 28 in peak oxygen consumption assessed by cardiopulmonary exercise testing.
•
ADVANCE OUTCOMES. The phase III ADVANCE OUTCOMES study (NCT03626688) seeks to evaluate approximately 700 PAH patients, randomized 1:1 between oral ralinepag and placebo along with background therapy. The primary endpoint is the time from randomization to the first adjudicated protocol-defined clinical worsening event.
Autologous cell therapy for PAH — SAPPHIRE. Conducted by our Canadian affiliate Northern Therapeutics, Inc., the phase II SAPPHIRE study seeks to evaluate the use of autologous endothelial progenitor cells (EPCs) genetically engineered to express endothelial nitric oxide synthase in patients with PAH taking conventional PAH treatments. The study seeks to enroll 45 PAH patients in one of three arms: (i) placebo for six months followed by autologous EPCs for six months; (ii) autologous EPCs for six months followed by placebo for six months; and (iii) autologous EPCs for 12 months. The primary endpoint is the change in 6MWD from baseline to month six.
INDUCEMENT RESTRICTED STOCK UNITS 
On July 24, 2020, we granted a total of 916 restricted stock units under our 2019 Inducement Stock Incentive Plan to three newly hired employees. These restricted stock units vest in three equal installments on July 31, 2021, 2022, and 2023, assuming continued employment on such dates, and are subject to the standard terms and conditions we filed with the SEC as Exhibit 10.2 to our Current Report on Form 8-K on March 1, 2019. We provide this information in accordance with Nasdaq Listing Rule 5635(c)(4).

6


CONFERENCE CALL
We will host a teleconference on Wednesday, July 29, 2020, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing (866) 209-9943 in the United States, with international callers dialing +1 (825) 312-2282. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing (800) 585-8367 in the United States, with international callers dialing +1 (416) 621-4642, and using access code: 2886748.
This teleconference will also be webcast and can be accessed via our website at https://ir.unither.com/events-and-presentations/default.aspx.
ABOUT UNITED THERAPEUTICS
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens — having a positive impact on patients, the environment, and society — will sustain our success in the long term.
Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
NON-GAAP FINANCIAL INFORMATION
This press release contains a financial measure, non-GAAP earnings, which does not comply with United States generally accepted accounting principles (GAAP). This measure supplements our financial results prepared in accordance with GAAP as reported below.
We use non-GAAP earnings to assist us in: (1) planning, including the preparation of our annual operating budget; (2) allocating resources in an effort to enhance the financial performance of our business; (3) evaluating the effectiveness of our operational strategies; and (4) assessing our capacity to fund capital expenditures and expand our business. We believe this non-GAAP financial measure improves investors’ understanding of our financial results by providing greater transparency with respect to the information our management uses to evaluate and compare the performance of our core operations and make operating decisions. This non-GAAP financial measure enables investors to see our business through the eyes of our management. However, there are limitations in the use of this non-GAAP financial measure in that it excludes certain operating expenses that are recurring in nature. In addition, our calculation of this non-GAAP financial measure may differ from the methodology used by other companies. The presentation of this non-GAAP financial measure should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. A reconciliation of net income, the most directly comparable GAAP financial measure, to non-GAAP earnings can be found in the table above under the heading, Non-GAAP Earnings.
FORWARD-LOOKING STATEMENTS
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our launch plans for the Remunity Pump, Trevyent and the ISR, our planned expansion of the Tyvaso label to include the results of the INCREASE study and to increase the addressable U.S. patient population for Tyvaso, our research and development plans and regulatory filings related to Treprostinil Technosphere, Unituxin, the TETON, PERFECT and SAPPHIRE studies, ralinepag, our organ transplantation programs, our efforts to re-open enrollment of our clinical trials in light of COVID-19, our expectation that we will sustain our success in the long-term, and similar statements concerning anticipated future events and expectations that are not historical facts. These forward-looking statements are subject to certain risks and uncertainties, including the effects of and uncertainty surrounding the COVID-19 pandemic, as well as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 29, 2020, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

7


Orenitram, Remodulin, Trevyent, Tyvaso, and Unituxin are registered trademarks of United Therapeutics Corporation and its subsidiaries. Aurora-GT, OreniPro, Remunity, and Unexisome are trademarks of United Therapeutics Corporation.
Technosphere is a registered trademark of MannKind Corporation.
Adcirca is a registered trademark of Eli Lilly and Company.

8


UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share data)
 
Three Months Ended
June 30,
 
2020
 
2019
 
(Unaudited)
Revenues:
 

 
 

Net product sales
$
362.0

 
$
373.6

Total revenues
362.0

 
373.6

Operating expenses:
 
 
 
Cost of product sales
25.9

 
26.7

Research and development
89.7

 
85.9

Selling, general, and administrative
105.9

 
39.6

Total operating expenses
221.5

 
152.2

Operating income
140.5

 
221.4

Interest income
7.2

 
10.8

Interest expense
(5.6
)
 
(12.2
)
Other (expense) income, net
(8.2
)
 
30.4

Total other (expense) income, net
(6.6
)
 
29.0

Income before income taxes
133.9

 
250.4

Income tax expense
(26.8
)
 
(45.3
)
Net income
$
107.1

 
$
205.1

Net income per common share:
 

 
 

Basic
$
2.43

 
$
4.68

Diluted
$
2.41

 
$
4.66

Weighted average number of common shares outstanding:
 

 
 

Basic
44.1

 
43.8

Diluted
44.4

 
44.0


SELECTED CONSOLIDATED BALANCE SHEET DATA
(Unaudited, in millions)
 
June 30,
2020
Cash, cash equivalents, and marketable investments
$
2,570.1

Total assets
4,219.4

Total liabilities
1,125.7

Total stockholders’ equity
3,093.7


9
 EX-101.SCH 3 uthr-20200729.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 uthr-20200729_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 uthr-20200729_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 uthr-20200729_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 7 uthr-20200729_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 uthrq22020form8-k_htm.xml IDEA: XBRL DOCUMENT 0001082554 2020-07-29 2020-07-29 false 0001082554 8-K 2020-07-29 United Therapeutics Corporation DE 000-26301 52-1984749 1040 Spring Street Silver Spring, MD 20910 301 608-9292 false false false false Common Stock, par value $0.01 per share UTHR NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page Document
Jul. 29, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 29, 2020
Entity Registrant Name United Therapeutics Corporation
Amendment Flag false
Entity Central Index Key 0001082554
Entity Incorporation, State or Country Code DE
Entity File Number 000-26301
Entity Tax Identification Number 52-1984749
Entity Address, Address Line One 1040 Spring Street
Entity Address, City or Town Silver Spring,
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20910
City Area Code 301
Local Phone Number 608-9292
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol UTHR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Page Document Sheet http://www.unither.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports uthrq22020form8-k.htm uthr-20200729.xsd uthr-20200729_cal.xml uthr-20200729_def.xml uthr-20200729_lab.xml uthr-20200729_pre.xml uthrq22020-ex991.htm http://xbrl.sec.gov/dei/2019-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "uthrq22020form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "uthr-20200729_cal.xml" ] }, "definitionLink": { "local": [ "uthr-20200729_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "uthrq22020form8-k.htm" ] }, "labelLink": { "local": [ "uthr-20200729_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "uthr-20200729_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "uthr-20200729.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "uthr", "nsuri": "http://www.unither.com/20200729", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "uthrq22020form8-k.htm", "contextRef": "D2020Q3Jul29-Jul29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page Document", "role": "http://www.unither.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "uthrq22020form8-k.htm", "contextRef": "D2020Q3Jul29-Jul29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.unither.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001082554-20-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001082554-20-000012-xbrl.zip M4$L#!!0 ( $PS_5#%^GN#1P, '(1 1 =71H&CE"1HZ@62<^+W]7-LQQ]<7"YF$7H%J9C@?2]HM3T$G(J0\4G?>WS 7Q^N M;F^]R\')Q2>,G[_=#]&UH,D,N$97$HB&$,V9GJ*G$-0+&DLQ0T]"OK!7@G$J M0JZP4&%/T2G,""):2S9*--P(.;N&,4DBW?<2_C@[,@,5$PI];ZIUW//]^7S>2KC! =FB8N9WVIUV^[S3]9#)DJM>Q/C+6N7% M2$8M(2>F9OO4MZ]'1$%>/=%3>;#W8LM\?NJL@VZWZ[NWJZHJW%71^ 7^\X_A M@^LF;W""D.LV-HN%U(AOI3LF:N242FJLES$HXQ%T<3O IX&'TNX>"DJT&]Q, MY7(N2YW(ATBKP@@71BW#X"&_&LXQ0)H@) I/"(FK8Y2%*4H6:8HC151G?';R M.*^F0#4GS$Z@VG-F^R-D7&G"*;R)LRVQ3SC781O"0:<91;$45*/(=<>@Z/I$ M4CO49MBHQK"((\*)%G)Y8YX/(XND7'/Y7IA8Q*Y%##XW0'3.'"9V)S@%;LD5C=L/M?3M!^!SP3$W>Z-D]#",LO(N%1Z1IAY)?8SR@)RYI_# X2@) M;,-GU9I40%L3\>I3D7 MEW9E.M^WI*E]POP!%RXU:1(IS4EJ^>X*NXU35JZ> MZJRN:[8AL.HLN<@6&A/ @DZK(ZQ4KM08@A-&U;MSY&U56FP\/12CUBZH I%K M; $7XIH .I;6[4NEP5BI7 D7^DT(PKG0SLF&\F <,SX6:<3$[&[9R[?,>Q@C M=TSN91O6_L.T'TL1@]3,'&)*!W=G,)4P-C<*"7.S_T4FD-_9/63?/][?OGFM=0#; MNKR1O)EB%@W:YMIJ?@@7_PQ@Y!R0M5A%+_Q-Y89GHB#\R0>NO-D%F3BKLD>X M\K%O_+';*LF#>P]FZYF\L;%F@M/RED71Y'9S\ U!+ P04 " !,,_U0 M9!P8>3T! "" @ %0 '5T:'(M,C R,# W,CE?8V%L+GAM;)V206_"(!3' M[WX*QLX4JX>EQFHV=S'IDD5C](KT:8D4#%#;??L!3A>SF2R[ _^[_WX/QA/ MNUJB$Q@KM,IQFO0Q L5U*=0^QZLE>5[.YG,\G?3L7A8%>M6\J4$Y-#/ M')2H%:Y"ZQ+L >V,KM%:FX,X,4+.22@NI%"'41BVS +JK!A97D'-"LV9B^S* MN>.(TK9MDVYK9*+-G@[Z_2&]9MU5A(A<9"1LD71 AFG2V1(C[U#9R/X#Y"+O M?NC;852G69;1>'J56O&;T)=-Z>:M6$:?1"CKF.* )SV$SNTP6L("=BC,J\7\ MIDBC?%?!)%S7-)S3F?:O],[V<.F_Q\_<0Y\&6?#]>#?!?1PA MQU;41^GMTN_[<"9Y(^-S%#[^D@?Z/Z]V)D'G0)501M:8WOR$2>\34$L#!!0 M ( $PS_5#[S:UWH0$ -0% 5 =71H&UL MM91=;\(@%(;O_16LNZ98C5DTZK*Y&Q.7+!KC;K$<+;& ;IV_WZ ']-L71;G M;EHH[WG/3\=G)H5T704=ITH0OTY&RNW2"UW#H?\N?7#)-*P&46$S M[2IW2>]:75_W;6V ?=_"(#)<;'-7+OGDH3H](.V'IU3'?G%I">."[#6$YODY M2TV3.\&"6;]!G8!X$GEM*#<&Z0\U9K"B16XO1*SU^4=@)2B7?^<]L[DZ;G#' M L02]*6LWWE<&S1S?CHMEH"/K;D0]P>G6FAW:+B[R4XZ<=.]VG-=>-EWB:"R M(!FPD*I/SOZMP\8'4$L#!!0 ( $PS_5#G38UZ@0D "-F 5 =71H M&ULS9UK3]M*'H??]U/,KEB-[/#Y" MRVE1H>K1KE:620:PFGB08TKX]CMVXH00G,S-"6_ 4&?F-P_S?SR^)/WTQWPZ M ;](./ M4U)4 )4DJ\@8/.75/?@Q)K.?X+:D4_"#EC_S7]E@L'@1:#8F>?'S8_WE)IL1 M,)_E'V>C>S+-+N@HJYJ^[ZOJX>-P^/3T=#J_*2>GM+P;FA!:P]6K.O>H?QJT MNPWJ7PT,[SO*W=F3- M&L.__[JX:L8YR(M9E14CPX+0T-'6WWC&0C0!9F1T>D=_#=G 6! CJ#<&]<8 &LN#Y&];@WX-AHX4 MP"S&.:D/];1<3I.-OV98C@ MQZ1D2Y#V15DYV@-TN<=P1-EQ]:$:;+"MER+* MN:GJE%B,G 5]:]0;<[A=5EVS5Z30\AS#3$S#"ZW(2W#LHZ1M/HHL+ZU6CMXY MCX4:%9G&5<N^K'QTDL6MMBK1^JR!>I (L% MZESB]2X(C;_P^^,E:0!>5#IEL %ACQ7D@+T?/4CF?\,3*B1XA(&+*J^>OY&[ MO%YF%-67;$K2R'1-'V,8FK9E.R9.8 )7W40AMR^D&N]9%XM,8!T*U*GX92$' M;+\K>F];"*@RHT_#K0!#-?@_T1T5, )Q =!3^QI [ M*EX.R_%+73(W59T0HBL Q#HHL\EY,2;S?Y/G%,:!C^W01-!SG0 '0>3;;3_0 M1X'8$D"T]<.L 9:I0!,+L%RBJP!A:+S+@#YY2:T#^%'I6PF\@K!S*2 +[/B" M4,R_M1A0(\$OC/-B1,L'6C:W4J\J=G:"Z"/K^AG1,4D=#&,_0)YM(@P3G)@! M7%VLA#;RQ?2AUM=A9+*1\7?0I&0S!RR3@CJJJ%\4&?/:YG!XI=RC1%:?CG92 MVBDG/7S?BZHTC69+7#HI\6LLR2?DR^/TAI2I;3N&BSPC\%'H8>0G,5XMK; ) M(S%G"31\&$'5@< BD:B'1"#Q2J^TA@2@]Z((F>A;/I > M/W_Q7V?S\S%;+^6W^>*1L&5_L6$GGN\@GWT)$+03WW"7_6$'A4C,!+*]'$8+ M+!W8C"3#B@[S:(*\KUH1GD<6\[10X9?0.%XS*;7 M;/GM(B^(D;H>2K")73- %HXMSS=1>\*&8S\6/'62Z>$PXEE&^KW= '4X\+40 M/DN2@L@KG;[Y20E'')T^X;P!9*=L5 "^%]$HC6%+,NI$A 6#V.;7\IH^%6EL M!2'TV +*BGUHVI$9X/9$"B,WDM.+0/L'EDN=K+Y84&>3%(L(/$&M],1-32I< MR+0+98V"1R<2X-Z93&1&T*42:1K"(FFNRWPM+TOZ*V?C3:'E)R&35NQ%40Q# MT[#93\ONV-)(\#:19"<'5LKJ F0;4-(KPBP%Y=(G1C7#\!/4KIE74'A<(\OQ MG0E'>AA=UE'C(JR>2SJKLLE_\H?F>G 00.1'5A+8OA'9$/IQA-K.$LLRI,0C MUL6!M;,(!U@ZJ7M))9_**1:C1GE72K.CK,(+F$ .S MWQ6],1&S R<.+6]P>S'BCO*7@G+\@I>+314G W]1U^_RGUS>TZ*]B>1!-_&\ MT/#,*/ -A +77W<1)YBWL(4;[KFXFSR@"21\YT8AT^E@L;^7,4H0##]H6]EWD86:;Q$Y6 MUT:@'7.?,\BUWK,&EJ' 9BI^%4@BV^^#_FF)24$0E XQO(F@PPYJN(ZO",7\ M5-?$X9?%%9WDH[S*B[N_,E9X>39)@_J!$Q<[T/9BWW1<"#%>744-'>ZWN$@T MW;,FUHE &XG?$3*D]@NB9TAB=A#AHT,-VX/O\(("I>-+024\U3)3^'5P69): M.80-JGFC?OUI,.77VUNV4,$.BI"/$@^'MA>ZD1>LW6,8(?<"0J&+GO7 D@U& M+Z*!13;0A.,7A0K#_<(X$#XQ<JPC@578/?T25320 M",P>1+3%AD]'\DC?G904AM*M)E4^7*=$9/3(SKZ>#?/F.J\F)#4":/87?7]4!"N>#XB.0M\85RV$Y M?HE+YJ:J$T+\&(_GHWLV 4CSV4&.&P=A@+S$P+:)64^FN;X5 R%WC4LUWO>E MSV4FT(82_.0O.6#\A_O>6 E> 17#I/.(_Y+ GJ.^%*SC:T$M_AM'?P4._$]@ MXBDI[YB+_BSI4W7/3D8>LN(YM3UD1WZ(4>*P#D+7\-V5DIPXY/[$8)4^>E;& M\CG"-AM8A /+=**/8$IBW&^00Q$4$XDD/'W/8+X)I,,K.A >7R]:1K'U&*8. M*FO9O/S#7["MLP_M;_+%_X=R]N'_4$L#!!0 ( $PS_5!KOE^@2@8 !XU M 5 =71H&ULW5M;&@&(SQ> 1.''^_1'$=N+X4I\ >> %$]B5=K_]6*T6 M\OG+8IH:]U(529Z=#N )&!@RB_(XR<:G@Q_70WK-SL\'7\X^?/YK./SE75T8 M?A[-IS(K#:9D6,K8>$C*B?$SEL5OXT[E4^-GKGXG]^%P^*1DU"=IDOW^5!UN MPT(:BR+Y5$03.0TO\B@LZ[DG93G[-!H]/#R<+&Y5>I*K\0@!8([66GLEJK^& M*[%A=6D(T="$)XLB'AC:PZRHYSYBDI7X8DO^P:RE(2%D5-]=BQ;)+D$]+!S] M^GIQ7?LY3+*B#+-(#LX^&,83'"I/Y96\,ZK?'U?G&X/,,XVJ5"=1/AU5]TOAYEHN3=Z6!>3I3V7$_J(E+Y_7&O0ODXDZ>#(IG.4NWNZ#A[ M7J)%GBS*Y+B*_T5X*]--8W;II4IMJ%5A(E68H%.;NVNTEBW])LMVC7T]8,OV M7DJ5Y#'/6H9X]["=V'Y=AJIES/<-W++]-SHERG8MWQZR;9OS,DQ;MGEKR/9L M?@,QRFTSCV3!3,E"Y\!ZK;G0%Y;RU;AOS+M/4\E%*;-8QG5:7TV6YM&65X6> MH':ID-').+\?Q3+1<$!2G0RKDR& RS7KH[X4U!/3VZ)48;2>-*VMY%@/"9:;E"(282: /& 38$0!O6IY6*V^NEBBU:OH*JAL]T1[+7XH$ MP'1MB 2"+C4]5W ?,[$RW/-,]QC#7P:8JLC(52R5KF@&AKYS)Y5:KBT':H Z MWN764QJJ:(LFFXI+B=$L5-J$831)TGBE795$C0.6MP*<-K/+:*_7%5]GCC^$ M?4,V0,!F"'G8MDQF^]"AKK-V W/A-X@_ZFO\FR#8$1%X5B;EXY4<)Y5_6?DM MG.[CP2[1P$,.PIP#BBS3LA$70("U$QYM0@.S;S1H <".6$ U.^.*H2(-QWO" MOR$3F ZVL#:7:! A1K[I07>=Q2AI$G>K;W%O@ERGCSW3-JDP/=?%T.(?^7CP MN7\E&P"?8&Y1Q(#KV(03XF%KY0; C#0@@-TW K2!8*=$.,^B7,UR54="[]-* MR?*YMO:1Y?'AY>"@9F!SX&/"7 LQ#@07B( U6,!B1U6W>TCB]),D;>+9*65$ MDLIO\^FM5 ?Y\2P66)8-'>9"@AEU.IY&_"1?G ML48@N4N>^L!'T&"/3N!#2[C89E@?" .6P-!9NL5M1ED#3N!^),<.^"(.X@PD_NFBQ%;+8YZQ^PW63E(/XG1',7W( 73 MI]_53?Z0'4.)9^G -PD%KLYZIH\!LCQ$^ H8SARO"2$@Z#4CW@SB>_"A+G&^ MJTN5WR?5F[8C2/%*)0 F%E0SW-' MMYFOQ0(7.,)U*7211S!DC#CXV7A?\"9A[UUKLB%Z'87^ITK*4F8LGT[GV7*; M4^R)_T[9@''B LOD6.^9N::RL,2ZT &6WRCQ]ZX]V0:$'3'A.D^3*"F3;/Q5 MERHJ"=,]--@6#$C5,G&X#2S7Q\AV .!\7>Q2N\DK"MB[[F-C_#HBP*62%2^E M+D_K-^C5AQOJ^]W=WO5@OT+ ;>8QS(3+J8;(\5SRS&@(::.DT+L.9&LXO@\Q MSHMB+M7_IL>66F!!3SC"1L 7E"$(+8[@RCG/=$ 3DO2N)=DRFETM(C*:ZR7N M$:+;FZ1,]VT>7HL%T'9M @6S/6';W/9LUUOSW#29V80*O6M"-D2OH]#?J+#Z M+/[Z<7J;[RL=-F0"P#BU 6)">TJY[?LF!\_)S6OR1@+UKL_8!+J.'W:^B"9A M-I8'/FC:)1K8CD\H8:Z W$)<^X'0\P8(@$;Q[UTWL04$.^TB\JE48TW0OU7^ M4$[T4C4+L\.?N>S4T-@PR\.4,V%K+Z@#L;-FMNW3)A^[HI[V$=L \ID;GT=; M&%[H"VJ0_6O0&U]ZU/C2);OY]V_(I>^/0%Q;9=?@ TU M%==E7-UL5P$#U'3L?ME(2VFL*5ERZX'+^]??&P[X5F"Y#K<_?.A=';"#81",SSY\F$PFE4FCXGH/'^YO/^"KFA]LU_5% MQ0S,@T___A$_^O3O__9Q*+@)__VWC_]1+K,+UPA'P@F8X0D>").%ON4\L#]- MX?]@-58NQT]VW?'4LQZ& :M7ZU7VI^O]L!YY]$1@!;;XU/LYM/I6\/&#_!4& M^Z!&^]AWS>FGCZ;UR/Q@:HN_'PQ<)R@/^,BRIV?WUDCX[$I,V*T[XLXY_]+^TKCXW*ZUFL?UD^;GX]9)_?BT53_Y MTFR>5FL'GSY^X/!_^E;T(QK9MAQ1'@I;B/^,FJB5K.4'A6L.(; M?0^&PX^C41-CT]^>G<68FR;L?;GO!H$[@L_&/^// GO!.:/# MV'SN].M$SJ/OVB:\0ATC:[=41<^X$9PQB[$1$S970#P!L2^ZYQNAJXCSM@AT.41:]?:Y6:U??JN M,^J-N&6?,69Y_R]TK ">JACNZ%VGM$R@+YR =Q1>,D7GKQZ"B>KZ>P[[ VP MW'MXGH]%&%B&#VS6&[L>1PX/@(=_!G[6IGTG#-YB]&P;*] MM_WMET;]_(OE<,>PN V;Z8=VRLU\'Q N"(36@CQHS8L#=>#1$SCELT85GDG, MHOGJ>3>CO:7'SZP !C-6[7:9*5C\I6!Q[0F M\='*4[TQ:-^],-Q],Y'X0$% M<5OM!VS1^1.2OC4.$"*UT^;YQP_PED^[G"9!T1./P@D%>_#<23!D[H UJ[^R MJ>!>V86YE_%?FY#Z>YT\+6[5CS*[O.K>]CIW/>9?7728'_9'5H <+W#9EXM. M:DIX5C7:%KW>63:<#+L;>S!2B7TS*XP#Q(&5P%D90]#&+>X\V(+=<.]'B5U5 MNI52&GXH1_O/T)X"(D^JY_5VB:5DAO)59^PYV7)XQ7V3_P4/WO]^>P0G8O(I M+,YQ0\> [UF!SP8Q[_0D[V0#T,= FLG[)^(B-29,UV<1"3A!Z;"P\V%S0) W!S!#A1AOMS_'4$J%O((0-?^0! MFPC&/0'_L6TV=J59""_%4^)P9D'H.4AJ"XS'- M\2T^C>2 038&N A:*4S!9T/^*%A?"(?Q\=ASN3'$J<)7RV/XAAA9!K-A.-LO MT7)KY\SGELF^P9?A',"\"X9]FP=!B=T,*Q= +=TAMW#=-&!W:(D!Z_T4!@ 6 M!KH>#"P#< :\<@6>*TQM:2QJ&.P6C!.",0GKQO7"9MBV.\%)XAI3XFN9#X)M MXP[8%VT@'M<4Y1_QXLQG[06A. M8YXPL0!] &?BZCX0C 5GQN&]]]-'[KL*=15V"4<,1(;H*M%9(+I ),!1X MH0]L=836PI3=A*,Q[83EP*D">/&OEZ.Q#:_E?6"W=U,_$",".GS)-4,@]WK MJPOVC^^=V_O>K?3O?+F\ZEQU+SM?V6WO[OO7^[M-8+A"8=CR)FV!/_\!]OQ, MY UA C9.P@=T&'9H"G9H B_A'G[ X%4V\LD2$S\-,0Z0@3-_B"@#0N9'9ULR MVM1B$M^?4_.J$3XL8+Z._#TY@(,RQ9[?+GP&7BDIR0#9H?[Z]X/J ?WNC[D1 M_?YZ9]V(>P^6(Z?'P\"-/B!WE?QD8IG!\*S=KK2K]68C^G'\ZWG?]4S0A W< MY[$OSJ)_+-$ SA],J< $CH_S=?Y^4#M&IU]@X@\O_K.:OQSQ^/37\^BAQ;_5 MUO^IE>I;Z?Z4Z[':+_K6BN-9,-TDI<\;-(M4G_Q=<8;D1Q)M=0GU!/4\P4Q? MS3;6<3>40PN^8+4E,5A/#YY>NB*$B.6-?S(0,:!'_5*E_Z7:FK4;L<1U6J_= MBM;JK;@?>D*P;_"'H<]ZTE;H>Z3V,]#X5^_1FT,"C>\!Z(AG0\L$)KH=5?\% M&&@<,%"-Y+_K[X"'5Y#*SA!R01(5C0#G0>PY'NH:#Y]NA(?OY@]B/2:T_"#> MD0%\J%%(JUP:XNW!DW0@O3D/V=)>:!2]/XIJ[?V41(5>7U:EQJY5S$(?JCY+ M?98Y6I\^R^*L+VFV%7JM+Q:/#MZ9[\8AA"#05ZX\*V\)O7? M",]KMVOG"_T_*5;X[.&F<3QN*8+UX%/CI%Y)8_J]WQFLB!?>RC'DE:PC2%:0K;$84=UFK;I;!E\&VRSFT=W)&FR7=:^!M N+$'^/UU#YR+ M5R+ J"=W]%9WLIF4%YF@J5KU=#$)[T63SZI^5726K=&_3?37J\<:_1K]>XK^ MPW8KE5LKHYJ3II?=TLOV<-=L%0=U&^GK;VIY;D-Q=YWR;YW.#1/<^WKQ>9*O*5#;-+'F4^W4W4J*D[S[W+4.F?K^W V#O M'6;U2C/-%616^7O1V;@&_S;!WZRBK M$GU5\KYZO6G9(5:<>TO-7ON MFH+I(DY0W F;OVV(8YM!A)]H15]'I)G*_@LDS*KDS0=T/[G/,D M/33XMPQ^?=NHP;^?X*]6JFEL$PW^ H!_>Y&PA;D[>2;^Z0-U6X@_-]^A]]S_ MK/G?_)1?U14BN?&U%3L_Z\RQIG4$6U[7JKX-C1-YA H?+[:P8%X'3^_SPOAS M5*+Z9+S>YJV]RJ.!!L_K9IEF4G<">^$,+(<:\&!#)6?9P..S#V>-4$:"^Z&G M6A-A6RG#A3_8%H]?%%^<80>@I==B+R-W4GF.,NCCE8UREXO^[GZ[%AD3_1QZ M,^ _B'+?$_Q'F0]@1F?]&F>#O\BWZ=+]2\NE[?QE/?PB[?#X$4B)$2]ID?CD;<@P=\ M:C,%I#)V'8"RC^03N %UV).+6=EDZ#7=A%*N,?'*)2:8L09#JJ%,M;K[?D'I M.N3DNH?/$W]*USU)]PM*?&$%&]/]@G2_(-TOZ%7]@M9*P[>8@NY5I'L5+?0J MRB8>M=S,2H>;M\?FN[9"R@:+VM^CU_V+"KB^O8K#5UV\F<]MX9\]KXN\W8:\ M_$XDC9C;16!85F_QD1X6[ M%2/0WVS+>:\ 8<#&:?-EQ)8SUFE4\7@!WG'%#'37T!H@&US=JF- F1<< MD&"FI5*%-2 S#\AL NZP73DMC(M-Q[[F!G:--%7),XJZ_?;I2F3*G_=S=2(W M%F0-$&2F&V*)QDW$]MHM5J-10OW;5:-Z@><,+><-I(UW JN8-FC=HWE!HWG!8J[TQ;TAEA[PO:'0#RS=% MQJO8S#N33QI+?+]H9VLM>.V(/PH')&=1)0@2RI0NV9\'N$M9HS(T .TMTK_]Y>5&NM67KEL"% M\6WA^\)C<([""4HOFQ.^%(/+8/"[@ ?"?W9ZT<#PLH;\(KAU+<,BV,SFH$% MCU08GA%0R"08XGAQRD1\0/%T9\=#$^>X!X8GN"]6; ;LHVS@X82C/NPB;+&: M*#:Y 9RQ +Z*KYU8,/)LV"%\#Z?CL(%K Q^F1^$]X=B$QW%I\;-_^Z55KYV> M^\SFN+?XH O3'=@"SA2_D_(^4_Z*CY]9 9"P 4C^XIW%AU J:8;:6ZC9WU.4G0"*#0@/=:\+G)A.?ZJK$0G,P/$@-#CHQQ)RBI!OX+*E= MF6JJHQOX[/:^,".-"'0#']W 1S?PB1KX,-U$1S?166BBLQX36GYDI9M).E^1 M[G*S4YFB<:%;X.S%^O:D!A6.#I#+$\4J[&IL9D';.I6.'KAFAME M@!L5+@OUR=LSW9;@O5(!TY4>R*J,+CHSUN#?*OA;&OP:_'L*_L/C5'E0J2(K M,QEXK,GE76!7*U F>(YRPW#L,/RSWN2],&77H^)RB986,Z6.'?>&(@17$ MU/AZR;=9J9G#VM&;U)G)63VG;62\OF(3LJH?%=F%LZ_0/JRG:\VTZ2YD3!!I M:LC554O:-3=U'[*\0W.?F'.MO8LR8SGCS=LN-%EO9=;%+POSK$P:R4RV??&2 MZG>VZFV6WDY5W_C9]-\\5L_8+QFFR3;'9'N2JFJC)EM-MIILW['41K72VN7* M\U130Q-ZE@D]X]5E\@CX%Q:1>?6+_V?-_^:'>U6>?'(S:RMV ML%6I[XT328\*%"\VOF%>\^?UQ.T3C3]'.*IRP.NA7'L5T\);L=?-,LVD;L5 M>%AT9.W%'OU[5E!EW55AZHM!*G%!]2DJ[#F(/[49JS"V!,2W2&2Y%;[@GC&D M2C^F>(2EC4=8Z4==IJ:O*\*>*.CA/3/JBVM[[+S23.*52W2EJWADM[*&KN*Q M%UG8NHJ'KN*AJWCH*AZZBH>NXJ&K>&P)/+J*A\;%:ESH*AX%7)^NXJ&K>.CX MO3Q1K,:FQF8>L*FK>.B%:VZ4 6Y4N"H>:Z^MQI[[+V$$NJ+'MD@G[<1/6Y4T MT1!9E==%9\P:_-L$?_LX5>R;!K\&?_[!?U@[K1P7I[B"II?^*B_-SXD3;:%(5M=5D>3K2;; MO)%M8S?E.335:JI]$_QN[GS>(0N*J)QL0H7NJA( =>GBXKDM*A(=N+2LGI95.0(0HU.CU5)"M,=9 MI V^;8F0'>S!';;S)B5]Q+T?(H#A]\NE5:NG MRY;+F@&YSRZ-PF*SH;&IL9E-;!ZFLZ-R5EE EVTIKO/X<*N\-:/XW5Y1#%WG M+I$SE)4Z=]FDK$9K)^7LLJJ^%("O%QR0A_7C2FT'B,PHT]<8+B"&3QJIRD%K MIII-93F;(*L?IZE>F$TV^&;NW!/T<5>"K MG>RF7/-6;ZIT<;[$"M^IB!==*\FM6/[Y?(VY%Z3@TN/O4H9NX]U]BYSDK>]' MA3U5'NW%MYRZ.)HNCJ:+H^50"=+%T71Q-%T<31='T\71='&T5S.+# BU\-I5Q;;2^EZ.-GEP1K[6PT[::5*B=/@ MU^#//_@/6ZFR%E*%3NW\%/8TW_/MR&5[L&L6"'7[73CM5OB!9QF!P(6B3A\Z M5K!&H\^ZSROM'ARGRTC.FI&YSTZ/HD(S7:53#4T-S=T;7KJH7]ZA620X-K]%+*46"!!P<$(S,^X9[IL['-'79X=]^Y66,LOIC99A/$C9-4 M3#6KO+, +#+G@#H\;J>J89=-_K>G'J*<8[!]HCWTV0)4#D%4.TESQ9E--J8; M-AQ\ZHW&MCL50GD=QZ%G#+DO2,/;<5W$G!DVU9T4H=5V>(;X\?Y">_/J*1K: M!8%VWJ";JA"SAF9VH%DD.#92,=+]]GYFO][MJ_M#O'O9NN)5I]O9JK?9"C;5 M)?&SE;?R6&NN\'))DVU!R/:P<9HJ;/_%2\]18;P]=>QK2M\+2F^UT_48U ): MDVTF %QO[*0W0@X%U:LJN&:GX"J6Y[0_JL2X3Q.'99A8+1;GZO.18&/X@FOB&E._ M/%EF)\7,)C"UL6=A^5-[RLQ0X/RX,[?_&,$4[[7I68_"P>*GG-5;N *L(#3W MO!MZT4699QGY.Q[.&HUX8:9X?F&9.,M*UBHGTZ_S)72N8;<\=MB36#IBEP[L MNRBQ*Q%4TF\;\@N#"M71(YIZ !]V/"L20VN MXE\>N.7X])'M^K[P&3+LOT(KF#)?&"$,8PE_&;1*4UO$\'+%LH.G,;X%.;3H MI::?0R]ZQY@_@%2"]?XH\P',Z(S;$S[U#]0R.'/@Y/Y^X#>J%XW/GS^??NZ> MU([;K6:KVSP]Z5U46Z>MSY^;GSOPA0]\;@=VO*X5NO SNY_=ZN!7KE/^K0/R MJ<<]!T;WL\8%$U,4:HK,\D&L#& ^)A(\$E'$I+CYK]#']#;@5&?LT%*5YY_W MK<,+[!"G'GWD R7:\!!\ H3J)RM@E.!/J_+H2E+36HQCEHWK4/:))\)@CLYA M$M;1DRQ!,8)#8@U'*QD"O05>8P$3M+P12F 8PWN0?WD\8C8(7EA>F5:'&R7P M3SC,(?PUX#_IJT: ;W>6=E[N+[YV!>O)&-H//G5@ZPS7,2S;DL?M#A)H(0:\ M"EMC.%[DD:8J;W^8*$=? GP88AR@1%'';?* 'YV]^6XDAI@S,HM;#;]UL/X& M4%5_;Z0K_[[U,O2;#_:N!8*?0-^K27&UW-$%YC27<>O5X#P@WJSI]:M]+PA-'?O@!6/KN!-UB5B!&_G-= )[3XS2_ROSZ M]N8L,YK(N84EKVL>NCXH_?7\T _':W8-UG[^Q 7.Z3B@[K(?/\ KUBA#1:MY_^Z55K]4+T:A(*]_% M@V>K&'9AX4J##IMN0?3-1*\#[1PXIU8/CJ9# [: QM!T^U^T.UQ.UTGJ5S2[?X$V"_E4<;YD9L&^A59!]_; MA>O3+YR#^S/W+2,KLKVPXGOW$KI1.=U)_3JM.Q=(=];TM0%]G6SN?\H0?>W/ M7<.%98?ILD9W8[^^(+_I/7"R$]+=4O[::_9CFQ2_FY+M&06 CC;2W$%SAU=P MA\W[8N6?.Q3MNNI/"K_"% I8!G\0S E'?>%A"3+#'8U<59;79VX8^ %W<'XZ M)[;PZ]N;L]P;U[?< ?GS"1]8RG"+-,(N6_$6S>86HH]>LPU:O\U-,%$!T-W8 M43NNK*&[:/I9DFT_Z=C9'K0W#%)X%^L$N/?F#:F?OJ[/D!&R3PKHOL)YU\V9 M,@3G%5UJ7OWJ_UGSO_GA7E4Y.HF3V@J@S K'KRDOS98W8%4UZ,:))#9UQ"\6 M9#"O^1-[KHG '"6H6MJOWF@J9/-R9&*>U^MFF692M\) 9)ML8@5#; XR%IXL MBA^7R7=E7Q?#=2CFBLNB^/ ?JA*/_@[U)7B@\AQ(-8XVQU$]!SC"E*IZ]?R) M7C/T1.U/+Y]/> M2;W=/JY^:;=/J[WJZ>=VH]9MGWQI5O&$DVUJUN['*I@M8?$)):+^]"9V/(O; MB\_3KPN=87I_LIO;ZXOOW7O6O?[VK7?;O>Q\O?SOSOWE]17[?G/1N>]EOP7( MI3QP!^!0#H0W8@$0*1NZGO6_KE-B$]E\!5N!V#QT #'WTT?NNU2U$HX6:-ER M3, S(D(VF\ MPYO.[T=G5!/S5HRP<\P4F%VS53]G-^%H7**_W'OB<0J8?*\4<3 A3IOG\UGB M*>R01OW#>=VA2, M@!?-X#"' M4!S,**[WY@!0@3.P3%RK1\ZI=W>/-[^?+KQ1%3Z<=I.Y?)7_'Q M,RN ?3!63??RJGO;Z]SU-AEC_HV5S5!S[; OHN^%N&_UINP+1^0:U6X'+/& M +6U?9EM0_HN<7X0FE.4(PD /,@Z8+"B&FV$1O[%HHH08@ ML P?J 4;6L$W.61!!0U\[1^ED>6$P:"3;C] ^$2<,< O)Q\^_/BJ!(-S&WX MX0_=";4QHOQHGW'#T^T$+DA$LQ M+NG+P+. HA] 57O ]G]>B6&-4"10-D1"GH)0M S5^LIT?5&1/HD[($-K +P( M%S-;&.R-\(2@M\VN&=:W&!]"U0S[P=HG5?W91C_\]5-2-H.A' KA^R1[!BC' E(Q30X8+$5+VP'^-^3X1 /8 M\' "FC6LR4:52E43E"T9!R*8HM0<6+:@)U$C R3'NS(&^6>YH1]M#[[3$K(? MX@_'G3CX;4"^,<7CBJNJ.S=?P/!\M+PB!G!22HXEW1O 28 3L'K0Q,+X,=N<: M%N("OF0%-JQ>68F7SI#CKT X=.A GC:"_S(I.[^B[+R0/*K<\7UX%R'B)A:_ MOR?$[QF[S^+>W2'E5"+3%Y" EK$1(%L8\1]"UE$/@:8 (*$] X&D./X(?('T M*M!,B?>$8["GD8']"YB' [LT#ONVTF;]"FP@0P1+W99D*QZ834)A9 4*@-G; M)KG<: ]4G]?OE;L*^^*ZDLU<>.$#ZYBP>$M*4E2\OUQTCDB&AF-4(G#W ']B M@ +)F-+'MA2TZIV*^:"*;^(+.3R@MH\=^E?P.MBWH05":I(\*SDS1H;HHX6U ML^%84#JB8!K8\!3^$P=PPX!:$3>Z^&L6]CZD1&+%FO:VRY='0.#!!CY02HMV9D=',@GD>J-1QWEGAB DF= MT!]:XS$1GL".214C8,D!GP.*BU\-#C MGBB#QF3/KQJF%'B6^0#/B9^P6-]Z%,##:>#92: T(?T:-*T!%A"5SC)Z%6A/ MXA%5\BXM0^[L-X%^#UCMW_AH?*Y^M4QV!]HY[=H-B&]8<8E=H,3O@'B9@@HG MMZ/KTI9WX5AQK^B@E+DV?UH37$X?>^8*J<"!=AMZ),1&-*)-1::E]RY$4X-> M$D_N!A;//K,+]9UOZCN]^#N@,3QX7/D?:#35I#=J#=['SJXP5\,UU4Y'GSR$ MEDFF%<>=M7SBVB :C1 L+H'*Z9A.RP@]3\K-T(^V=7[C05$EFQ4L"FH,3(_8 M6+V5W71^CU=JJ.U'OP#V;K4&T\AZA%-V3')8KL&]7."0/\**A'!F((>Q!P,F M-]\7\1@@P< XQ*%@TO0ZY<2JL-_!:'Q$FXY:O5ND0*!G%.P/#GN#(P9N3)GR M'Q[B&S;4AOD!HN4<3-#*I[!LY>L8PPP%F(6QMF[Y?@C/RX;#D4B,AE CCF'G M')S,1>^/#BQ9.78E*"\2KMVNZXTK[! ? ZF,)(U5R45,P-B^ @@6:9*JFO,) MZ%32/X<]I)'84$LD5H&YA7C-+VH.71<=OV& 11R1*ZX)1^Z%EFY%II/I-#Z)#>VKNR&^8C3LA MB6SBAO BCMUVX&SQSS@.Q1C#@W[" J?U6$!2L 0OI.;6]"QH);$EI;I!PUOD M:4@THK5/RX(_2Y6)=$4+]@BU+?$0M[C'(P4>#.3M$T>X_N?E1;G6AL\&0EKH M'H$Z:?:3.@?(AM_N OHK\(0(']+R9W^%Y%W%/9*^(0 ='-PT4HGGV4R\@?&: M?3H1VS4(B28H83[Y2.WITG$]"?:5PZDUQ%[G$IPN>@"0BAT7F1)2?*#(#F2# M'Q-:8ML&Q#FQU[EO>%8?N6/??90M#,FRAO_2&URTFW%*Y+56&CUJ^XL$9TB_ M$GI+)%;&0^#9L!I' BMV58WXE/19D#ZPZAS:T:M/"*1'[V9V*E)+ NI,D#!#J_&-CWP&Q++8??VZQ&+T*!H^@J_JBXYB,8 M%_[,* 'X ;M '* F$OEE@'L!CE#<]:?Q!(;<9 COJ0BD (!SA2GXP6D.R2##"QLX8#U2)$YPH2BZ0B?R_I02 X(L=LDB"/U8 M3Y][NU2''*C".K@-WWSK7=WGY#I\Q8JN,1HBNO"(G.Q(6C+8RXFL M6U1E903%0-YX1YK"D/HI^R'"!P6'0/>6 Z M#Z[4J1<6,>9DC26FGE BY4W/@@Z9U+TBU4G25;Q:;H,B:T[56R4)1 -&9"N% ME2' #$\X9Z5BX)@SX3RS.>*Y@Q5NAY(^6<2N0-"#,-RY7-F"F^M^KLMGM"TD MX4'W-U =*2.FYD\E 1J$R]G"0C,9LD5R]\U#MNK-E#%;=*%P\JJ,RQ?$;>T M05N^;?A\V^O]]P:7^60268]N@+:4=-RY8!$*V"@_QC?>]2?5]GMA#!W7'\,[ M1>J1LQ"]<\Y6 ";[X92:-G=&FULD39+CG8M_=JZZ/7;]_;Y[_:UWMX6P&X_C M7HSY@T:O1N_N),M=Y^;F]\O;K=QC VH[H0?6;_FW>Q4(NC:A7F-W#[%+CG>Z M)KQD,62^.W@EY8Y$%#N,9E8?['ECZ,Y"3LVI/[:Y;_%SLCTTK#2LGH;5M2<< MZ\9S%:H6SET+^__ M:TM"(E9M*NS/(;J_V2Z][O]U(Z-6A\'P6K4>^7V,HW9)NWP\\ M#..%HTRPM$1\?/?ZYN)(N:LBCP]%LJ$G7_ECT!>!'JN9@\@*Q'HD6-*R6Q7N ME#F<=VR\JWT8RMB]%;X5+#8U[WF3D9FV-:+;U41-JFAW DI8(5=,B5GDX38M MC)##B#89@T)7EY.A<'#<*(!#WE\AN>$T%AP\B3O)F4]0.IG5O%1\QE!0F&OT MWMD5)!N$'OUI=E7MQ_>?RE?'0F?@VN9B8*-<1.@8-EXQ3="_'5UJ)[^,5Y[J M-FHA\&$04BA /%-R=M^TB@6!6UL1R3'>B\J?4W8JZ+\!IP)'>NPPP:SW@Q>#LPEN.$9,\ MC"PKJ=&08@"ODP&B%/0B8[,H,(,;46A6 IIS+N3(>SWGLI5!V,1 B''(NZ8% M'K)(<1/T!*F8,8/(Q'=5I(8@U'E\;)GV5+G1%^C77>6@5Z%4"?\P908L7ZAD M*$)SL>BQCM!\R\B'U?Y)9H) ';L3DX@#H^R]-TDWDX[9+2:;I5=3MIP'L-'* MYC2^PZON?;71/JZ>-MI'P*?%#\G)Y!618,WCV;44,B%4:9"Y8+950NTB8F(^ M\#ICJ(*9)#N>K#K\PXN;2[HV'Y%*F+%0909518CX3V0\C"7T*-6(Q-O)[0E@I9G#]Y[1@RP_,W3/Z,/XYV@R5X4.WTY+36 M;AX1?#%O-:8R%3XC8]%H)$ :!7(!MD!1-T)?$CSJ7+A$1PA3QF9%*3@\D74# M1-BGO%,D*<5DYH-Z/G_M'"V%9])TGEE@(AXXH?#)N!>EQ '9FY),9NKEW-Q@ M\&(0RLP@5R;TF\A\Y5#(3(;YE@7_9LM;(?F;[9.3>F.5Y'\BM1Q/4YJ_K%$M M4\HQI7QCD3E)TR56:YPDY:XTZCRP<]P1S >SQ8,)!F]:*NUR+BA5&8:&Z$0%,)-M83.9+5\T3C"/ MI,@#-[#ZX?2=5_$)+.Q0C4FY>12KET2?95HN?#*DR-0$[,:@[XP EQPU9(50E4+\@VL8X9@K^9_$,>@5=T\P10M9:NVLQNA DR%^ M*]DDNK$B9K2>#4:^9MS\R-N&F4 BR157<\-ZDZ;4]UTL78M\#*V:1T0&P PO MZV O#K_\LXL5068#81 TS'(T#F00-#D$HZC[;0-S2]54(H3.RJ+@>22+AQ#_ M\CCHII39-I '.PB=N 3(FIN'>=P1MP-[;H&_P2;*K"NL*8+^]9]PL%Y?A6EB MW0Y,2[0I+'L!4840$K?1O5."SI,UU52&Y9L(@,6KM8T&FW]U\GY\EU./@IVR M(L;HS@,UG,CW/SOE);]SPG";3SR;$W;HM<8[A?C"DM2LF\[OBP21R7"#]KN4 M8SRM%SO<8)606"3F#;VX,]QF_"Z?[+MFM=4\.6VMLN]J[<:"U@2T4UIEHBV0 M6=(XHWO>>J2P@"J$7L3X;6S67P IV>/C:8FHM-Z2?M776V]K])167"[+_3D% M>XQR4,.13#;FOB_3 _M36:$K$;HD?F*>+7I&!67>Y[.XJ^8F;\U-(OFZ!??0 M3CG*AGK "H_12?WDI+62H]!%\4\+:P;84W9:K1(/B+3?.=:"-LY+V,N,G2RS MDC7,0_$+JK9'W"(:5JH-4=8[I69Q\U\AN=!A2C#WP#5)W9Y0XW+0X2 M93"P; J(N'(I8 CKR^%NB3"@@I2835R*;O&(NK,:%[Y,QCCK4-[N\ADD@+XP M+L4F%PG88D 0 86A@.!CA[V;KG^$53J%*F\!SS\ ]H7RF8J?6&UP_BWP KR# M HYA@JR?.@'MU+*_&: 7<%G1Q'60 *5;A3Z/'+1*DUA<$L6XX!UVDA'A$%@+ M@+0,O.+EWL@_8X?6T9S/V;=^,LKF]U6ZH<1!8DMPT0N/GL-KX#U//S3WOM5# MRD!J>->:E]7JZL&GF>!S+F]9K0"&7173$]<_7&Q4F]D;>:XY=7%]^[/=N][%^SN_KK[!_M^=7F_ MB;!<;HF3Q9#.:RST82_4/'X 02F+C024BPCTT:Z=X!TOTJFL88_U@K "C:^J M9"%7Q!( P/#0;46>FCMZ"C@@DBI8_3>J]'EAHU6H_\J4KEPK\:6,P&S '%0RA_.AH] M*MA/X994^4I^#?WNB:(+TA[A6 P8&)H CJ%B]F;%"P25Z$@4/+OK=3& L_=S M:/6M@-6JE7H4&-.588SL5L@2D0[[@I$4K?(?^&\93T*KP$(L5*O5?40V2=[< MY(4RNF<-;$M )<1HZ"ONF_PO]E65$KL-P5XY/FD<'QI'A\VC3$?OG>CHO;=@ M@-WKJR^]VY[T.'S]FGU^]:>*U!YB20;@3YC)[SH#T"X0]4 &?PK3$0#[:2F] MNH<<1#+P>ENRQ0VNNWC VF?5JGP?KXPJK,?]@!1%#*$EJ;VP#+P;HVJ,%GH8 M\-K$XE0A\+!UZCW_MP:OJA\? M 9NLE^OU5AVOL#W1]UQN&MR/_2X+\XIC[^/"OU1L2.6\?E5N/D=+/)-VNP#R?U6KEYTE3E] MO[_LWF7_X!7^DT8CE9:,JE,-7"-4;<^DY@'8> B&,G*LSVV4]F:)H ]S-YVZ<(R,!3(&BJCQ?7'G5P%""F,_[0U" 0:^3(=;<\6ETU!6MX_:G0!AS9, M\\>!KZZORK]U.C?LR^55YPH[=['+JR_7M]^H?5<>D&Y1L4G?I^K47):C"RC/ MD\-Q.\!GD3^-X$_$GQS7D0L6W$./L!^'C;@ /4I0PRPN571WOKHL>L<\\HVA M"*?8=0@HA1!<.C#7&8J^'.$(44:.&3@0)^Y)3QY.+@K!E34D51;1@$]*< MJ8::ZFL$W-.=O"'@-M#\T1>YM.]4C]C'9BY83M!RSMAA[4AJVQ3C9&')\%E5 M=E7+$>-WXN !++OH..A+F/4;[8?F@PC.V6%=O0PC.%7)4MAG^ [6),<-=E3B MG_0S#FFK)8^(S@5>2A*,3!0E U%=!;3! TU0!03JB8)+Q44?(J/Q?F24;= M"I*@RL? Z92/L!G-E&XYHZS$.#H+*X>&I#V.*6R+NF":%HI;R5L5!TQ.CX3L M3+Y:_FS_EV@BBI'"74$_C>OY*CI>NHC(:6+-:GLOX[8_5>X-?.J!*K1[2A1P M5(FG47:"/TXX8Y).$'PO[#-($5G W1<+%U,JNS+.K%D^&2 7D>C*2%^A9B@S M;)A805FV-+E_9D^$0X6Z9ULB,P/$W"['_5/HW*H@DQ@,@D4#$=91?SVZE<0U#&715I";J8$ M#=."!S&G68*4E)_5"Z&2\\O,4)F& [H>59B0.A35\DZT-,#\$^*-6[R.NHKF MTU/S29]BGCL-")2=/SNW%^6OU]=_7%[]QN[N._=TM9 #(_1NUI)6Q4@K\"PI M13$G0 *"/P-+(\4U9@?T1]5("T@&ZPB7;=?](4MT1L-$+:=4_UQ)\=Q1T@%_ MO?$PW5VP.^0X,MG]J\S'1_JY%91OV#'(555KMX^Q%].ZT:)%@<4V0O.+&(DR M0)-9_^LZ7<2ETT$62!&K:@S+5ZA0:B7%X_0[M1 5F4X=F60'3IK+BJRY3+=C MBGK"J-X*R7+(Y"1SP_X;4PYQ-MU MY&N)&O)K,U]+<;9C:=O5:2CGH<2VDG2UU<#?K80 1(=,N65 ,[*YE^0!*'\%225X JQM:TR 4LZO*-];JL'1\/Y:?H<]!>++RO5\;O'R M,-*Q/,O_(4<+'?590+L_;ZA(&T!F4\\]B\WC/(J!BAZ-&YW,*DG/M>W +/U9 M8P^UB3)SSC*4->@OW%NJ'JHS#HR3Z/U4L01==Q1W*5#%7U"S,K J$N;-A0D5 MB?)S2<.+^LB CD/*7O(LU-,5[./DB[]"*N^BZM\\L\?D?*0B\:K4/DR#["1O MFGBTE/P8T/P0HK^)6 X<2-P Q0?5#!$]7+M/LLVL$JBDM/O0/U1EK[GYYX;%6^0^R\ R;6Z.H MT4"@^N1$L;=\@$'[7M_U(I?(K&O.:Z4T28/U1YGHBA&9@4OWW)S((2-W>Q@> MX%,5'0<["=O1RK'-U5@V%?%44\8E6W5A,Y=4K:@X%1DBJL6CJH:?>$UIGH.5 MR'1Q(F,)1;6[HL5YAF[Z3_5-_U;Z^%(EQ8!:SR7:$4:J:RG6P1"S<54(:=-C M+HV,S_.X26U.?%GR\^FK*;KH"?R9KYN,\KBV;"DN[EB*%>IH>%5+E,9_U:#; MM@NWX3I.%E^1::TK=A37%I6NV>6"=E'VSS0LS^!/KZUG6\#ZR:=-"UQSCY$A MQM,J..-9WM.-Y[7"[;'BTAUTT=N;Z]M7WOR\S72[UU=WUU\OL7O.1<)%PZZ_ ML&NP[FC.KW#8O,VD#R\=-L(FH=1'2?S$.R/4255K44RJ/MHY7TR\W),!S45>WZ$JDP7>E4&57+K%I.C%F8K4Z%J55@L:*VF\,K4\6OL MB[/H'TM\(4,EBJ]G_HM!Z-0VM)J%5\=C1EL0'?GKP]-(5 MF"+"&?]DOFM;)ONE2O]+M35K-V*)G[1>NQ6M-458*';ZFTL)"#T'?;TH4:C? M8Z-:6I?3M.?8:+P#-EZQ-3M#2])"?DEZY@Z1@$6E!K8[.1M:)HB:;:A9^NB? M//I:6W.#5)(B'Y+@\+O#0Q/M[:--SGF6D(MZENN=_6(80@P&;PV M$S@%EUG MH?#/GCGT^G-\8)O[L';5M#&;XOYIF*=;Y<[/:85-O-&$BR2C-#8SB>V\-](-]SYPO[/!@O9"JFDG7CCI%Y)HZ%GE5T7@"MK]+\= M^D\;E<52@=X2K?.DOJB['7R1"\9Z]EEV&OW(-UZM%9> M,*W\O6&=DA/G"]99=7ZECAI92O9XS@ORG#>T /1;]/7MS5EN6=O*L%W>=675 MCA?8YEGW&:7=@OIQ9=5U1>Y\1EIS*B V3RJ+<:ZYQ&;A_)FW:[*1-H1G-E'8 M:J="8589X3[QNXP"*IW(S3SWRKTZ>"=LS)LL1:5&5*J*.;(R7!*Y5 MM7JX/^PR9^!LM+?K.LL\@\W7)<9R191WD.;O[-[%EL7':3":12^NUBQSC<7: M<;U2+PH6]R;,[9>(KS6KZ?AGUF1\IF":5:::,W"B<&\6 9R%\T]> M8NB_;'JQ!9Z93?2=IA+F6>5_^\3FLHFG6K6RF-N?94#MCU%4FF589"XCF6DH;//]P+IR2>4VUP@X55SZ*RQ([HICWX(>M M5-#-#T*UCIIU"#:JJ0SN@NBHV;_QV1E'+%+(_^%)!C3:]W7J:W57T\&G>GL/ M$KJ*EOER22R=];%&L5 ,G@7\Y[M<[K^!4ZS1R%6LGE9ALXZH^O%>Z[ 9MN!OR[SG0NFL!R:%Y7&EHJS>[DN%*/!U) M\(KS;L!YFVZ(%9PW*73YOK9.FKHW+]Z&[!JLM>III;:+I6?21T3.I3%T=X!\C;"&/S1UT3=I89XB^ M]N'SF1L&?L =G-^F[KY">?6R*DP*(#,T MH#+)V7)O;#SA3DL979-&7F;W&";SP%^G6^]_9=[VNO>]^[8-WKJ[OKKY<7'?SE<^=KYZK; M8W>_]WKW##[K9&W>LY[A)68Y#+YM6Z[CQ\'3*4B^43_?[BH3WY\C=XP:UJJ1]@C$SA&VKO_[]H'I OP-/,J+?5ZS[WAH)GUV) M";MU1WR)28ZX]V Y!H6KV@=.*'-Q[XXB_YQODC5 M![&J$G/-YL%Z148.T3K]]?Q@B>NHX9_XTU-_F_WI7=U[66VP]5P*Q8Y=G4L4 MU'KM9K167.9F^JZF7CD^KZ;P]Q3!WLTM_LJX+]WVQ MCK(RXA-/;3Z4ZK7V/B=D9QU[ML7[EFT%UKXU9JR5:O7C?>Y_EW5D^H%K_!B" MYB8\_V^_M.JUTW-24H)I(3EEHU1M-W+5">\I5XKZSJ+AO*SE'SQM6&]A]HOU M9?#GOT6_]%US^NG?/WX8!B/[T_\'4$L#!!0 ( $PS_5!0QJY[M1< %>J M 5 =71H[?1$]'& M>C^ 9L/68X:=:>" CMFX+Q>R5,;:EB6U)(.Y7W^9)=F6<95L:.@&NCMF #GK MD97OS"J5C_XQGR;DAA9EG*4?]N1]:8_0-,RB.+W^L/?IRN]9>_\X_NO1?_1Z M_QI>_$'<+)Q-:5H1IZ!!12-R&U<3\F=$R\]D7&13\F=6?(YO@EZO[I0?6%$8 M1*JMC )3U\S(LL:ZI"NZK=@2'4=C^_W\(%054U=UW0ADJFFR;H6Z1#5+'QA,_NL!#R;ZMRHN.?@UT\3\.8*T/$,Z* H3O MK@'.!GL0I!S\V4PWD M\2B;I56Q3336&^$P)G>8SNZ<;DP[2X%0-4 .TFD0AR5_+@;B(1@*; P >.1/ M;P343V]$"'73<*T)!\&R6.^\XE\A4D]FLV\HT+3HLS<)@ MQW$@8&J[!6=)L[(7%&&1)90CR2T@IVL4AGDFF+6&";2F''$T;:$U .2C>1T$ M^1KAVV@N@+P9PW&OY+$9)V0PGI;2, F#)%1%]G0)YQ&&QMU2TFK [9X7-,2P M8,VSLQ%P?D62['[#E_ZJ\;IJ".=>@CDJ40A4MN!I+*I)=9?SY&8)XGD0"BU$ MT]3+X]B&D&/1&^L0\JSYFF\5TN)^JZZ!MKMQOLU8FP.XM0,FT(HS4% (: M3G,Z#R?\N1#"Z9"%^5C@;1FH8VW=:Q*:[RVF6VRVN5:@ 7!=;A2/8U 22 UZ M>5!P(M>-)GR!Y\[:J<)RAPX+%!BHT!-I8@T31B,\!)?1" ]1.OVWP.\BA#&B*1)4((IX,HT^(F5^@7.IT&7[XA;AMQ'%P3THUX5FDB6L:$NPH<1ISO MC7B2!4Y9'%4(0PI!-A+QLQ&7B^L;(X$;&?'\!Q9LNI.O M50-.50?#GNZA %L \)J+M)8K>>.\-PL["Q<,S#.#,T'= @!\'R/T M+[RH,^2S8#Q)!$:[ M ?)CJ%P<0^6\+HOL5ZB'K0;\P$*0=BX@ J)P2TP+HO#+3#4DB@N.G5_U1#C/ MN)79>"RP;P@2)&W=-J[=@N=Z!;:@HX+9L;HEG-,9L8H[- C4K@K2D-YW95E5 M3KI=&;80F$BQ7-= GH *C#;79J=9NH/'A!3QGM<$42]' DM9P[CA0YGE M-5 MP[CEDS%%[:="TC=YY;+A$D=A[BO,>!L'+O3L@JJ0(.Y?@CJ"\ZT5<7Y1(*75 M-GI DPVMWJ+4//(GJ2CK8"!>!BA@<<6CPR)DZHRG^'9Q5>_>4OL3YS8@,T(R M&BA1:SZFBWY\ZJ%A[[3Z@I4)C%K*-6K@B<6QQ +*/6@!:WY]2!8Z,T7,1%NO@B+ M.YP,;%7:X65@S"=U1]5\QHJB*7X4-:&A*#U#$(^E62B**0'"]8@<;U&[0FY& M@ML'7:$6?ULZ3L,JF N6SF"<3GDNJ"0!H,.@;JUT\"U!/(?PBX9KPKWHN:JZ M]:LB2,MQ5DQ9X13'T7N2M89&*O"*=7-!BM>Y:=\*#>4-K/GV:QO*2D\Q6H&P M,*.H83P5$#ERRO7BN+LG6"! ./M\<7 MV@$!"$]< D&E%0!\P@L)SB%T%8N" MB06$ETJ&5!"+(:3#&5(4U/,L3@65?WX[GB,16 -N:;SDU;B98O.KVVCFNL-V M/E)QQ N6&&LC?BY3U]@[T]X:+M"PS@(*OW@R3_B*Q4+]?_W1J@H5]#H3^#@& M$D3V82(Z25$#N29.4"NLO2^_.-%5FN"GM]=49,(8K"N+$V[WM5OPY)1>;]G^ M;4+:Z_:^$175@7BN$8>+JG7LFM'U?@W<._[K7XXF-(C@]U^.IK0*"+;NX5X- M9-).EE:XA"O(B?9(6#]]V*OHO.K7!\_ZK&,55PD]7IQX.^K7SS!TOQG[:)1% M=\='47Q#RNHN 1:-8;#>.)C&R=W!53RE)3FEM^0BFP;I(8.5\?_1 UG*JT- MLMT3UILGP1TF'^ DM*C_C*.(INQ/@)_6*5R-^;RZP-C7Q:#MO]5_ MSA+%[K&?>R0-IC@PC0\&L( (%^$GP?4>B8%!?A!6X#X4W_0TS?3TX5!7+=^R M)=/7#5M5;,4P![W;S[V=&NZ1VC%]V -/=C#*@,E!.@Z2$M;"?AWUUW!__%*\ M%-APYZ#%#)*3-*+SW^E=:TGF8*"YABGKKNL.M.%054P#,=6-H>.:NK=\>2),F2I>BZMH%]?YTIRY2U/#[" ARK&4P#6 YAA>>#"4M0,.KN+:+K_7F) M"L# F)U_V"OC:9X@\_OK8]33M>=@CV4V*]@3*V@<-"1DE."0D$ETW9(R$N(' MBT_ 7L-GXY@6A,U*N>&3<_+[.E'N=V9S].]/TLR1 ^6RJ#UK68&[=<$0'".Z M/&*?3Q4< H6>J2 MXSFZI'FV[>F^90XA.)!V -9D?YKTP8< ME7F0\JQ'G$):%5><'J.B#_-AO\6TK.B5,T^K?QY$ M>!RYE]!Q=2#E\[I_G"+GV7-[@A0M07*XZ%-E.0XYQR&K8)10$M(D:: ?]J0] M]@S+"1?/#[>ETZ"XAO"-H1?,JFSQ 3N"7']R&T?5!%K#XD=9 K&UI4<1@DS42CK*JR MZ0*G^NE SN>DS)(X(G^3V+_#-0XH0,TV>=O/S0CMCVHJX"?-+-A'W9ABG>49 MX#E.LMO&S!TVS-5AE"<0XK__33:DPWM2O"18G\G)AG0_2IJ-AV)HB+3LT?ID M/9A(V(,]WM9SC+(D@B$^G9Y<>2ZYO!I<>9ABZ2@E4*(HU?.TCJ78?5^7U+V?MRY M6M;7D8J\)0%2'HR$PJ<*6+ +[_2*7'CG9Q=7+PV[\UE1SH*T(E5&+FF(5<": MC+)*LH+(.GD7_5)_DHU)-:$O;0& ] Q:QA#*>?-P$J37E S"B@"VLJUJ;TDD M'XL$9C%(CPN:9T5%WBV>:0 I#"TK0F_P[;N"@6GTR\$C3(+ '6Y:SJ\;[VAS MH-M)7-$>QOH4S-IM$>1[G=995N2E>;:&EB1#WBFI#N3LOBWKI@?FV?(=T]$L M8\ SS^,32[(XK]GKW4*++-Z[^^ MGHQ/9*D?&0<_EZ/?PG9[Q7;/ZQ70*\CI#'*YDCA9 ?K(]F7>O.=^Y\V!+P1I6QNJ M!;5)4)++G(98"HI(G!)G$H"-*GYY6H1_EB4X90EU:UE"U595B0V8NAMLYVK& MTU0KUIG];7+"'8R3OO))ON[*GN][MC,P3,DV'=- GV0/7=<<^@ZG<'V2ABM; M<5F!DW'J[6PGBQ[FH7"7&\ND%FM&$3P\LTN84I[AV2ZA^WZ6R?\)&6(9Q2R[A?CBVTZ^9IU_>;LZ M"3QVLNDT+LMVQ/I-2(Q&D]3Z^+8)?+)_L7^Y3[QIGF1WWUJ+ULU?![V??+_E MX2CS$LV?03XGR%>V!OFZ) [D]0=M2P+E7HNN/2K 4*15Y*>"4 \&$,I+UE"U MAJYB2"8&&(XB6X/!P-@,, 915-"R;'[] 0(H;P\N9$F3($$N\+ZLRZJ@M'J" M6/"[\.G!;-JEX/B@D.K-BZ=L+L73D&5C(+N.XKC*<.!YBF*I()Y#V?)4>VAS M*F"-7#KPYUEQE=VFVX7S,DZ Q(UXOG^M@OF49VK>8FS_.%E45K+H&)"+V4/7 M4G77-P>J++F>+;N*-]0@.=,&0EED*<59<5YD-S%[M6N;0'YT?RPA?!QK5&7) M&LV7/-7QP5"8IN&KGJ(/9&"-*KNN/] U2 MOR(F05C?$ U+W^=@*\,X#Q+BS6DXJ^(;2L[&$'33\D&IS>LB @*04GY)MG$ M2]BU>BRE5CLC?_^;!0[]L"0536@^R5)*4I:1O2<@0HIEFN@\/1>(X@P\5S9T?RV6 M^R,#$W&.TK)K^7(;80S)ZMF*K3P[=1ZP1_D=#FX\P93.A(:?\8@-"?*\R"!J MQHKI*)N3$4VR6Q*S\S?$SXIIC9W5^YV,XP05/2X)WC.<1C3"DSQE/)TE59#2 M;%8F=Z0,JK@- 51!BA6FZXS&*<@07JW@(VS!## ?K@O%&.% MKWR 2?F^!VE8Z8./0K>.F:MS?)KL6R#E ]T?.(XS&%J&88".N;(J:4/%6=.Q M/V$!P HLAL[2IEI6/GP;#E]X&05 ]PI$H(-D Y"3A'R"F<#0D8^7C%BVJ6F' M3ZN2"QZT?Y)FK;"X]F))WCI5=C%+:-U:4_1&M%"F6@>W\+S6.]DDCG]!%%7: MAX:/V^#O8/6+ES9KY>8DQ]<,R_-=31KJ UNU?!EWI]R!;_F>.M3;TG:9)7$( M9$RO/X*Y0%EXHZ*V6BB9-BL5R)FL!3U9:8G:VL' I:!ITG[=\L>3-5M=RMK M]7S?41Q)<@::IEBZ9CIX*$IQ7-FTW+44[[R@:-7PA3%V4!G]30'9R0YQQ.N4 M.5AP+VRM>#<[)VM13WDW:H[-[B2&=8K]BF*@\=R]!P M(U[S'#RDZ=E&AR">E.6,%C_%42".*NUI[\('B&/3X?N*X^/?EGHJ#%H12AT< MTP+"ZWSSQ#R147L7P3*0:Z<+B@LFXG<3 YY5=^0%V MBG:*"+151*#JJB4;NN+*0U]W57R5#O?0?475+-W6W+4TJ+;5=[(R8IJTO;"% M 03PX;+*PL_O21X4Y"9(9I3\I[0OR23':PLF/^*AU]VXM-J^DSW7'PXCZ MKJ]8BN;KF$#XQG XM"U[V.92H_6UTF]GT:>KWRY^TI]'?WVE)99I:89C.4-Y M* ULPU!D!\N_OB,C*VRNEBQ"OYU>9MF(E=&,+8W$U*$E$Q[ N]F9+JTXFZ8M8\EZ1K'ZI M427OL*%YR&IEB\8P%S UQY=C\)AM*_Y71CV%,R#O=!YF<[+B[9IIK#13\0?Z !R79AFFJ2B2#*II^KID.J[GV)ZSN7N^ MP/U7AKI38_X-D]G-Q3][:OO2Q>EDW*'"N-?*M0?QQI[*!+2=64?0]C1CV>.L MI*P5(-WLW.!MC#'+*.N;AI"S;*[D#B=GW\J)EB.%) X@!;V)2^@'-B1(0^1E M$+*;++$Q7C@=!454UGLV$3]U790(W@5K;WFO&8?]W=[B[9"F)=_7Q>F)6?[S M];Z7=^O0YI5 3W[KT.;%1B_^UB'1G5J;PKSW[#NKPKN_)L5*::YI;U30X',O M& -6!T%R&]R5*!J38OUJLZ&G#GS555Q'D755Q@OQ?,.0I:$)*8+A#K'/Z[O: M#+UJ#WA3@%L_*&=34,J[9SD62"EK.D8D?#SL G-(5>L.S$ M7QI])P,GA( 'Q&:O\XC$64H>'73@10LURJO;%AXYU'NRY85]"/S+&< #\+UX ML*^@^!6]E)2T8KYYC-^Z1&+@*PV*%#XIF:='Q_MEQEYP)W5$\!6K39OP7Y6^ M:TZ%A*3A$7](PHI/R03[)06 M/. I3D4Z',<)C=C?\N'2$D"TGFK;GLTVS_->PH//=+DB_C1N'="?)4LN#2,BSB?'$;A'5M]Z\$5A=_;3N6W+^Y-J^AC*8:JVI%OP(,%_ M=JZ*7B#^'AIYOX;ZUBS.:Y'71RY_D!G?X*[::]@<^S8OC%^>_'HZN/ITX;VR M&]V?8,KV'?WUJ9(OL[A@;X"4.U>".<=1(@PM M1X$4[85=(7<_P'A,S:T[?&J]*_-REOE8/6N^/^KJ-^]B<.Y]NCIQ+HES=G%^ M=C&XVOA^II?+Y><(D]\4G[^BQO0S\7DMZ_LQ2MIOR@#AM]!$!X(BT)O+VH=W M!X^5W)>QA?54A.B7?7(>S!(RV"X-' P M'-D4$L! A0# M% @ 3#/]4&0<&'D] 0 @@( !4 ( !=@, '5T:'(M M,C R,# W,CE?8V%L+GAM;%!+ 0(4 Q0 ( $PS_5#[S:UWH0$ -0% 5 M " >8$ !U=&AR+3(P,C P-S(Y7V1E9BYX;6Q02P$"% ,4 M " !,,_U0YTV->H$) C9@ %0 @ &Z!@ =71H&UL4$L! A0#% @ 3#/]4&N^7Z!*!@ 'C4 !4 M ( !;A '5T:'(M,C R,# W,CE?<')E+GAM;%!+ 0(4 Q0 M ( $PS_5 9F\@YWST />8 P 4 " >L6 !U=&AR<3(R M,#(P+65X.3DQ+FAT;5!+ 0(4 Q0 ( $PS_5!0QJY[M1< %>J 5 M " ?Q4 !U=&AR<3(R,#(P9F]R;3@M:RYH=&U02P4& < ,!P#0 0 Y&P end